These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1914 related items for PubMed ID: 8077666

  • 1. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S.
    J Immunol; 1994 Sep 15; 153(6):2562-7. PubMed ID: 8077666
    [Abstract] [Full Text] [Related]

  • 2. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L, Reich S, Slavin S.
    Cytokines Cell Mol Ther; 1999 Sep 15; 5(3):145-52. PubMed ID: 10641572
    [Abstract] [Full Text] [Related]

  • 3. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
    Weiss L, Reich S, Slavin S.
    Cytokines Cell Mol Ther; 1999 Sep 15; 5(3):153-8. PubMed ID: 10641573
    [Abstract] [Full Text] [Related]

  • 4. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD, Drobyski WR, Truitt RL.
    Bone Marrow Transplant; 1993 Apr 15; 11(4):329-36. PubMed ID: 8485480
    [Abstract] [Full Text] [Related]

  • 5. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
    Yang I, Weiss L, Abdul-Hai A, Kasir J, Reich S, Slavin S.
    Cancer Res; 2005 Nov 01; 65(21):9735-40. PubMed ID: 16266994
    [Abstract] [Full Text] [Related]

  • 6. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
    Cohen P, Vourka-Karussis U, Weiss L, Slavin S.
    J Immunol; 1993 Nov 01; 151(9):4803-10. PubMed ID: 8409438
    [Abstract] [Full Text] [Related]

  • 7. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G, Truitt RL, Johnson BD.
    Biol Blood Marrow Transplant; 2006 Apr 01; 12(4):397-407. PubMed ID: 16545723
    [Abstract] [Full Text] [Related]

  • 8. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M, Uharek L, Glass B, Vosskötter W, Dreger P, Schmitz N, Steinmann J.
    Exp Hematol; 1998 Oct 01; 26(11):1068-73. PubMed ID: 9766447
    [Abstract] [Full Text] [Related]

  • 9. Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses.
    Ji YH, Weiss L, Zeira M, Abdul-Hai A, Reich S, Schuger L, Slavin S.
    Bone Marrow Transplant; 2003 Sep 01; 32(5):495-504. PubMed ID: 12942096
    [Abstract] [Full Text] [Related]

  • 10. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
    Li Y, Guo K, Chen Y, Song Z, Li J, Deng L.
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug 01; 23(8):411-4. PubMed ID: 12411044
    [Abstract] [Full Text] [Related]

  • 11. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
    Slavin S, Ackerstein A, Naparstek E, Or R, Weiss L.
    Bone Marrow Transplant; 1990 Sep 01; 6(3):155-61. PubMed ID: 2252954
    [Abstract] [Full Text] [Related]

  • 12. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, Murphy WJ.
    J Clin Invest; 1998 May 01; 101(9):1835-42. PubMed ID: 9576746
    [Abstract] [Full Text] [Related]

  • 13. The role of antibodies to IL-2 receptor and Asialo GM1 on graft-versus-leukemia effects induced by bone marrow allografts in murine B cell leukemia.
    Weiss L, Reich S, Slavin S.
    Bone Marrow Transplant; 1995 Sep 01; 16(3):457-61. PubMed ID: 8535320
    [Abstract] [Full Text] [Related]

  • 14. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR, Majewski D, Hanson G.
    Biol Blood Marrow Transplant; 1999 Sep 01; 5(4):222-30. PubMed ID: 10465102
    [Abstract] [Full Text] [Related]

  • 15. Treatment of BCL1 leukemia by transplantation of low density fractions of allogeneic bone marrow and spleen cells.
    Palathumpat V, Holm B, Dejbakhsh-Jones S, Strober S.
    J Immunol; 1992 May 15; 148(10):3319-26. PubMed ID: 1578152
    [Abstract] [Full Text] [Related]

  • 16. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang YG, Sykes M.
    Biol Blood Marrow Transplant; 1999 May 15; 5(3):133-43. PubMed ID: 10392959
    [Abstract] [Full Text] [Related]

  • 17. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
    Wang SH, Li DP, Zhang YJ, Zhang P, Zeng LY, Pan XY, Xu KL, Huang YH.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb 15; 33(2):88-93. PubMed ID: 22730654
    [Abstract] [Full Text] [Related]

  • 18. Induction of graft versus leukemia effects by cell-mediated lymphokine-activated immunotherapy after syngeneic bone marrow transplantation in murine B cell leukemia.
    Weiss L, Nusair S, Reich S, Sidi H, Slavin S.
    Cancer Immunol Immunother; 1996 Oct 15; 43(2):103-8. PubMed ID: 8954144
    [Abstract] [Full Text] [Related]

  • 19. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR.
    Biol Blood Marrow Transplant; 2003 Dec 15; 9(12):742-52. PubMed ID: 14677113
    [Abstract] [Full Text] [Related]

  • 20. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
    Zeis M, Uharek L, Glass B, Gaska T, Gassmann W, Mueller-Ruchholtz W.
    Bone Marrow Transplant; 1994 Nov 15; 14(5):711-5. PubMed ID: 7889004
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 96.